The global castration-resistant prostate cancer (CRPC) treatment market is poised for substantial growth, expected to reach a market value of US$ 11.3 billion in 2023 and projected to surge to ...

This article summarizes metabolic reprogramming in prostate cancer (PCa). Early PCa relies more on glycolysis.

PSA and Ki-67 tumour markers may identify high-risk metastatic castration-sensitive prostate cancer and inform treatment ...

Prostate cancer (PCa) is one of the most common malignant tumors among men worldwide. Following androgen deprivation therapy ...

Monte Rosa Therapeutics' stock dropped 17% after announcing MRT-2359's target shift to castration-resistant prostate cancer (CRPC) due to poor efficacy in lung and neuroendocrine cancers. The shift ...

(MENAFN- EIN Presswire) EINPresswire/ -- The global castrate-resistant prostate cancer (CRPC) market is on a robust growth trajectory from 2025 to 2035, driven by rising prostate cancer incidence, ...